Equivalent lung deposition of budesonide in vivo: A comparison of dry powder inhalers using a pharmacokinetic method

British Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2005, Pages 167-173

  Lähelmä, Satu ^a   Kirjavainen, Merja ^a   Kela, Marjo ^a   Herttuainen, Jukka ^a   Vahteristo, Mikko ^a   Silvasti, Matti ^a   Ranki Pesonen, Marjut ^a  

^a ORION CORPORATION   (Finland)

Author keywords

Budesonide; Dry powder inhaler; Lung deposition; Pharmacokinetics

Indexed keywords

BUDESONIDE; CHARCOAL; FERROUS SULFATE; GIONA; IBUPROFEN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRY POWDER; FEMALE; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; IN VIVO STUDY; INHALER; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY AIRFLOW; SINGLE DRUG DOSE; STOMATITIS; TANDEM MASS SPECTROMETRY; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; FEMALE; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS;

EID: 13444292108     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02238.x     Document Type: Article

References (22)

1. Toogood JH, Frankish CW, Jennings BH, Baskerville JC, Borga O, Lefcoe NM, et al. A study of the mechanism of the antiasthmatic action of inhaled budesonide. J Allergy Clin Immunol 1990; 85: 872-80.
2. Snell NJC. Equivalence testing - the special case of inhaled medications. Int J Pharm Med 1998; 12: 245-6.
3. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose-response relationship. Pulmonary Pharmacol 1996; 9: 19-27.
4. Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl. 122): 86-95.
5. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurised metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-44.
6. Thorsson L. Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids. J Aerosol Med 1995; 8(Suppl. 3): S29-37.
7. Pauwels R. Therapeutic index for inhaled steroids. Eur Respir Rev 1997; 7: 366-8.
8. Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8(Suppl. 3): S21-7.
9. Pedersen S, Steffenson G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler®. Br J Clin Pharmacol 1993; 36: 211-14.
10. Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurised metered dose inhaler attached to a spacer. Eur Respir J 1998; 12: 1340-5.
11. CPMP Guideline CPMP/EWP/QWP/1401/98. Investigation of bioavailability and bioequivalence, 2001.
12. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6: 99-110.
13. European Pharmacopoeia 3rd edn. (Suppl.). Strasbourg: Council of Europe, 1999.
14. Borgström L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001; 14: 281-7.
15. Brown PH, Geening AP, Crompton GK. Peak inspiratory flow rates in acute asthma. Are they adequate for efficient use of a Turbuhaler®? Thorax 1992; 47: 239.
16. Malmström K, Sorva R, Silvasti M. Application and efficacy of the multi-dose powder inhaler, Easyhaler®, in children with asthma. Pediatr Allergy Immunol 1999; 10: 66-70.
17. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and pMDI plus spacer in asthmatic patients. Respir Med 2001; 95: 720-7.
18. Hämäläinen KM, Granander M, Toivanen P, Malinen A. Assessment of the systemic effects of budesonide inhaled from Easyhaler® and from Turbuhaler® in healthy male volunteers. Respir Med 2001; 95: 863-9.
19. Schweisfurth H, Malinen A, Koskela T, Toivanen P, Ranki-Pesonen M. on behalf of the German Study Group. Comparison of two budesonide powder inhalers, Easyhaler® and Turbuhaler®, in steroid-naive asthmatic patients. Respir Med 2002; 96: 599-606.
20. Tukiainen H. on behalf of the Finnish Study Group, Rytilä P, Hämäläinen KM, Silvasti M, Keski-Karhu J. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med 2002; 96: 221-9.
21. Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Hyldebrand N. on behalf of the Study Group. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 2004; 17: 15-24.
22. Borgström L, Lipniunas P. Budesonide/formoterol in Turbuhaler® is not affected by storage in hot and humid conditions. A clinical pharmacokinetic comparison with fluticasone/salmeterol in Diskus™ [abstract]. Eur Respir J 2003; 22(Suppl. 45): 237s.